

IN THE CLAIMS

1-68. (canceled)

69. (new) A method for enhancing an immune response in an animal, comprising administering to said animal an effective amount of a viral envelope.

70. (new) The method of claim 69, wherein said immune response is an antitumor immunity.

71. (new) The method of claim 69, wherein said virus is a species selected from hemagglutinating virus of Japan, retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, pox virus and influenza virus.

72. (new) The method of claim 69, wherein said virus is hemagglutinating virus of Japan.

73. (new) A pharmaceutical composition comprising a cancer chemotherapeutic encapsulated in a viral envelope vector having an adjuvanticity.

74. (new) The pharmaceutical composition of claim 73, wherein said cancer chemotherapeutic is one kind selected from bleomycins, anthraquinone series carcinostatics, mitomycins, actinomycins, camptothecins, cisplatin, streptozotocin, 5-fluorouracil (5-FU) and derivatives thereof, pirarubicin and pharmacologically acceptable salts thereof.

75. (new) The pharmaceutical composition of claim 74, wherein said bleomycins include bleomycin and pharmacologically acceptable salts thereof, and peplomycin and pharmacologically acceptable salts thereof.

76. (new) The pharmaceutical composition of claim 75, wherein said bleomycins include bleomycin hydrochloride, bleomycin sulfate and peplomycin sulfate.

77. (new) The pharmaceutical composition of claim 73, wherein said virus is a species

selected from hemagglutinating virus of Japan, retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, pox virus and influenza virus.

78. (new) The pharmaceutical composition of claim 73, wherein said cancer chemotherapeutic is one kind selected from bleomycin hydrochloride, bleomycin sulfate and peplomycin sulfate, and wherein said virus is hemagglutinating virus of Japan.

79. (new) The pharmaceutical composition of claim 73, which is an injection.

80. (new) The pharmaceutical composition of claim 73, which is an agent for the treatment of solid cancer.

81. (new) The pharmaceutical composition of claim 80, wherein said solid cancer is selected from lung cancer, breast cancer, digestive cancer, head and neck cancer, gynecologic cancer, urological cancer, osteochondrosarcoma, malignant lymphoma and cancer unknown primary.

82. (new) The pharmaceutical composition of claim 81, wherein said digestive cancer is selected from stomach cancer, colon cancer and esophagus cancer.

83. (new) The pharmaceutical composition of claim 81, wherein said urological cancer is selected from prostate cancer, bladder cancer, kidney cancer, renal pelvic and ureter cancer, testicular tumor, adrenal tumor and penis cancer.

84. (new) A pharmaceutical composition for the treatment of a urological cancer, which comprises a hemagglutinating virus of Japan envelope and an anticancer drug.

85. (new) The pharmaceutical composition of claim 84, wherein said urological cancer is one kind selected from prostate cancer, bladder cancer, kidney cancer, renal pelvic and ureter cancer, testicular tumor, adrenal tumor and penis cancer.

86. (new) The pharmaceutical composition of claim 84, wherein said anticancer drug is

at least one kind selected from adriamycin, daunomycin, aclarubicin, amrubicin, idarubicin, epirubicin, pirarubicin, dacarbazine and mitoxantrone.

87. (new) The pharmaceutical composition of claim 84, wherein said urologic cancer is bladder cancer, and wherein said anticancer drug is adriamycin.

88. (new) The pharmaceutical composition of claim 87, which is for intravesical instillation.

89. (new) A method for the treatment of a urological cancer in an animal, which comprises administering to said animal effective amounts of a hemagglutinating virus of Japan envelope and an anticancer drug.

90. (new) The method of claim 89, wherein said urological cancer is one kind selected from prostate cancer, bladder cancer, kidney cancer, renal pelvic and ureter cancer, testicular tumor, adrenal tumor and penis cancer.

91. (new) The method of claim 89, wherein said anticancer drug is at least one kind selected from adriamycin, daunomycin, aclarubicin, amrubicin, idarubicin, epirubicin, pirarubicin, dacarbazine and mitoxantrone.